Insights into the pathogenesis and intervention of atherosclerosis

Vascular Disease Prevention

Volumn 3, Issue 4, 2006, Pages 375-390

  Ranganna, Kasturi ^a   Yatsu, Frank M ^b   Mathew, Omana P ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiproliferation therapy; Atherosclerosis; Cell therapy; Gene therapy; Inflammation; Oxidative stress; Risk factors; Vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BILE ACID SEQUESTRANT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLAVOPIRIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINIC ACID DERIVATIVE; PACLITAXEL; RAPAMYCIN;

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; ENVIRONMENTAL FACTOR; GRAFT FAILURE; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOKING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VIRUS INFECTION;

EID: 33750716498     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270000603010052     Document Type: Review

References (190)

1. WHO Technical Report Series 916. Diet, Nutrition and the Prevention of Chronic Diseases. Report of joint WHO/FAO Expert Consultation. World Health Organization, Geneva, 2003; 1.
2. Deaths: Final data for 1997. In: National vital statistics report, National Center for Health Statistics. Hyattsville, MD. 1999; 47: 99-120.
3. Murray CJ, Lopez, AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997; 349: 1436-42.
4. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976; 193: 1094-100.
5. Ghazalpour A, Doss S, Yang X, et al. The Pathogenesis of Atherosclerosis. Toward a biological network for atherosclerosis. J Lipid Res 2004; 45: 1793-805.
6. Loscalzo J. The evolution of the discipline of vascular biology: From systems physiology to molecular biology to molecular systems. Circ Res 2003; 93: 583-5.
7. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-6.
8. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001; 7: 382-3.
9. Shaw LJ, Redberg RF. From clinical trials to public health policy: the path from imaging to screening. Am J Cardiol 2001; 88: 62E-5E.
10. Ross R. The pathogenesis of atherosclerosis: a prospective for the 1990s. Nature 1993; 362: 801-9.
11. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Nat Acad Sci USA 1973; 70: 1753-6.
12. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J Biol Chem 1997; 272: 20963-6.
13. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61.
14. Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: plaque to attack. Trends Immunol 2005; 26: 550-6.
15. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-26.
16. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
17. Libby P. Vascular biology of atherosclerosis: Overview and state of the art. Am J Cardiol 2003; 91(Suppl): 3A-6A.
18. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
19. Faraci FM. Oxidative stress: The curse that underlies cerebral vascular dysfunction. Stroke 2005; 36: 186-8.
20. March F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheromaassociated cells. J Clin Invest 1999; 104: 1041-50.
21. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
22. Schwartz SM, Virmani R, Rosenfeld ME. The good smooth muscle cells in atherosclerosis. Curr Atheroscler Rep 2000; 2: 422-9.
23. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002; 8: 1249-56.
24. Holmes Jr DR. State of the art in coronary intervention. Am J Cardiol 2003; 91(Suppl): 50A-3A.
25. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon- expandable- stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489 -95.
26. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 1999; 354: 1493-8.
27. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-803.
28. Li H, Cybulsky MI, Gimbrone Jr MA, Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol 1993; 143: 1551- 9.
29. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion Molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation 1995; 92: 450-6.
30. O'Brien KD, Allen MD, McDonald TO, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92: 945-51.
31. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-Selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
32. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997; 3: 900-3.
33. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997; 99: 1295- 301.
34. Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004; 24: 845 - 50.
35. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 86(6 Suppl): III43-6.
36. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human atherosclerosis. III. Immunocytochemical analysis of the cell composition of lesions of young adults. Am J Pathol 1992; 140: 907- 14.
37. DeRuiter MC, Poelmann RE, VanMunsteren JC, et al. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 1997; 80: 444- 51.
38. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996; 93: 2178- 87.
39. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-9.
40. Campbell JH, Chih-Lu H, Campbell GR. Neointimal formation by circulating bone marrow cells. Ann NY Acad Sci 2001; 947: 18-24.
41. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation 2002; 106: 1199-204.
42. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66.
43. Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. Circ Res 1999; 85: 562-3.
44. Loscalzo J, Voetsch B, Liao R, Leopold J. Genetic determinants of vascular oxidant stress and endothelial dysfunction. Congest Heart Fail 2005; 11: 73-9.
45. Violi F, Micheletta F, Iuliano L. Antioxidants and atherosclerosis Eur Heart J Mar 2002; 4(Suppl): B17 - B21.
46. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47: 412-26.
47. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23: 21-48.
48. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol Heart Circ Physiol 1996; 271: H1626-34.
49. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia : enhancement by angiotensin II. Proc Natl Acad Sci USA 1997; 94: 14483-8.
50. Grote K, Flach I, Luchtefeld M, et al. Mechanical stretch enhances mRNA expression and proenzyme release of metrix mettalproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 2003; 92: 80-6.
51. Lambeth JD, Cheng G, Arnold RS, Edens WA. Novel homologs of gp91phox. Trends Biochem Sci 2000; 25:459-61.
52. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-76.
53. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 1986; 137: 3295-8.
54. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
55. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumor necrosis factor alpha activates a p22 phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329: 653-7.
56. Tummala PE, Chen X, Medford RM. Differential regulation of oxidation sensitive VCAM-1 gene expression and NF-κB activation by flavin binding proteins. Circulation 1996; 94 (suppl I): 1-45.
57. Chen XL, Tummala PE, Laursen JB, Harrison DG, Alexander RW, Medford RM. Direct activation of aortic monocytes chemoattractant protein-1 gene expression in vivo and ex vivo by angiotensin II in experimental hypertension. Circ Res 1997; 96 (Suppl I): 1-285.
58. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
59. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93: 9114-9.
60. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
61. Tsao PS, Wang B-y, Buitrago R, Shyy JY-J, Cooke JP. Nitric oxide regulates monocytes chemotactic protein-1. Circulation 1997; 96: 934-40.
62. Peng H-B, Libby P, Liao JK. Induction and stabilization of IκB-α by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995; 270: 14214- 9.
63. Pagano PJ, Tomheim K, Cohen RA. Superoxide anion production by rabbit thoracic aorta: effect of endothelium-derived nitric oxide. Am J Physiol Heart Circ Physiol 1993; 265: H707-12.
64. Hogg N, Kalyanaramer B, Joseph J, Struck A, Parthsarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett 1993; 334: 170-4.
65. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 1996; 271:1424-37.
66. Stamler JS, Simon DI, Osborne JA, et al. S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992; 89: 444-8.
67. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38: 1395-9.
68. 1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-6.
69. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
70. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-6.
71. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
72. Penn A, Snyder CA. Inhalation of sidestream cigarette smoke accelerates development of atherosclerotic plaques. Circulation 1993; 88: 1820-5.
73. Ou X, Ramos KS. Proliferative responses of quail aortic smooth muscle cells to benzo[a]pyrene: implications in PAH-induced atherogenesis. Toxicology 1992; 74: 243-58.
74. Ranganna K, Yousefipour Z, Nasif R, Yatsu FM, Milton SG, Hayes BE. Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells. Mol Cell Biochem 2002; 240: 83-98.
75. Yousefipour Z, Ranganna K, Newaz MA, Milton SG. Mechanism of acrolein-induced vascular toxicity. J Physiol Pharmacol 2005; 56: 337-53.
76. Smith SC, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention. A scientific statement from the world heart and stroke forum. Circulation 2004; 109: 3112-21.
77. Garbers DL, Dubois SK. The molecular basis of hypertension. Ann Rev Biochem 1999; 68: 127-55.
78. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocytes chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-9.
79. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
80. Landmesser U, Cai H, Dikalov S, et al. Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511-5.
81. - and systolic blood pressure in mice. Circ Res 2001; 89: 408-14.
82. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
83. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
84. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
85. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo . Proc Natl Acad Sci USA 1993; 90: 6434-8.
86. Graier WF, Simecek S, Kukovetz WR, Kostner GM. High D-glucose-induced change in endothelial Ca+/EDRF signaling are due to generation of superoxide anions. Diabetes 1996; 45: 1386-95.
87. Maziere C, Auclair M, Rose-Robert F, Leflon P, Maziere JC. Glucose-enriched medium enhances cell-mediated low density lipoprotein peroxidation. FEBS Lett 1995; 363: 277-9.
88. Pieper GM, Riaz-ul-Haq. Activation of nuclear factor-κB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol 1997; 30: 528-32.
89. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
90. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90.
91. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end products interacting with their endothelial receptors induce expression of vascular adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice : a potential mechanism for the the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
92. 2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
93. Lehr HA, Becker M, Marklund SL, et al. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. Arterioscler Thromb Vasc Biol 1992; 12: 824-9.
94. Cominacini L, Garbin U, Pasini AF, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical endothelial cells. Free Radic Biol Med 1997; 22: 117-27.
95. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human endothelial cells. J Clin Invest 1995; 95: 1262-70.
96. Ohlsson BG, Englund MC, Karlsson AL, et al. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-κB to DNA and the subsequent expression of tumor necrosis factor-α and Interleukin-1β in macrophages. J Clin Invest 1996; 98: 78-89.
97. Brand K, Eisele T, Kreusel U, et al. Dysregulation of monocytic nuclear factor-κB by oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17: 1901-9.
98. Henriksson P, Hamberg M, Diczfalusy U. Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall. Biochem Biophys Acta 1985; 834: 272-4.
99. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl LDL receptor mRNA colocalizes with oxidation-specific lipid-protein adducts. J Clin Invest 1991; 87: 1146-52.
100. Wolle J, Welch KA, Devall LJ, Cornicelli JA, Saxena U. Transient over expression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression. Biochem Biophys Res Commun 1996; 220: 310-4.
101. Lee S, Felts KA, Parry GC, Armacost LM, Cobb RR. Inhibition of 15-lipoxygenase blocks IL-1β-induced vascular adhesion molecule-1 gene expression in human endothelial cells. J Immunol 1997; 158: 3401-7.
102. Hennig B, Toborek M, McClain CJ, Diana JN. Nutritional implications in vascular endothelial cell metabolism. J Am Coll Nutr 1996; 15: 345-58.
103. Hennig B, Shasby DM, Spector AA. Exposure to fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers. Circ Res 1985; 57: 776-80.
104. Hennig B, Alvarado A, Ramasamy S, Boissonneault GA, Decker E, Means WJ. Fatty acid induced disruption of endothelial barrier function in culture. Biochem Arch 1990; 6: 409-17.
105. Toborek M, Hennig B. Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells. Am J Clin Nutr 1994; 59: 60-5.
106. Hennig B, Enoch C, Chow CK. Protection by vitamin E against endothelial cell injury by linoleic acid hydroperoxides. Nutr Res 1987; 7: 1253-60.
107. Navab M, Hama SY, Hedrick CC, et al. High density associated enzymes: their role in vascular biology. Curr Opin Lipidol 1998; 9: 449-56.
108. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001: 21: 1451-7.
109. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function: recent advances. J Am Coll Cardiol 2005; 46: 1792-8.
110. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72.
111. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-6.
112. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-35.
113. American Heart Association. 2001 Heart and stroke statistical update. Am Heart Assoc Dallas TX 2001: 1-32.
114. Kannel WB. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 1981; 101: 319-28.
115. Penn A, Chen LC, Synder CA. Inhalation of steady-state side-stream smoke from one cigarette promotes atherosclerotic plaque development. Circulation 1994; 90: 1363-7.
116. Valkonen M, Kuusi T. Passive smoking induces atherogenic changes in LDL. Circulation 1998; 97: 2012-6.
117. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-03.
118. Lehr H, Frei B, Arfors K. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci USA 1994; 91: 7688-92.
119. Penn A, Snyder CA. Inhalation of sidestream cigarette smoke accelerates development of atherosclerotic plaques. Circulation 1993; 88: 1820-5.
120. Moller DE, Kaufman KD. Metabolic syndrome. Annu Rev Med 2005; 56: 45-62.
121. Bang OY, Kim JW, Lee JH, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005; 65: 296-8.
122. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute - National Institute of Diabetes and Digestive and Kidney Diseases working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002; 105: 2923-8.
123. Grundy SM. Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002; 105: 2696-8
124. Keaney Jr JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23: 434-9.
125. Block G, Dietrich M, Norkus E, et al. Determinants of oxidative stress in human populations. Am J Epidemiol 2002; 156: 274-85.
126. Davi G, Guagnano MT, Ciabatton G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
127. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol 2004; 3: 391-3.
128. Eyler AA, Matson-Koffman D, Vest JR, et al. Environmental, policy, and cultural factors related to physical activity in a diverse sample of women: The women's cardiovascular health network project-summary and discussion. Women Health, 2002; 36: 123-34.
129. Barnett E, Anderson T, Blosnich J, Halverson J, Novak J. Promoting cardiovascular health: from individual goals to social environmental change. Am J Prev Med 2005; 29:107-12.
130. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003: 42:1206-52.
131. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342:145-53.
132. Tolonen H, Mähönen M, Asplund K, et al. Do trends in population levels of blood pressure and other cardiovascular risk factors explain trends in stroke event rates? Comparisons of 15 populations in 9 countries within the WHO MONICA Stroke Project. Stroke 2002; 33: 2367-75.
133. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to prevastatin vs. usual care: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002; 288: 2998-07.
134. Smith Jr SC, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the world heart and stroke forum. Circulation 2004; 109: 3112-21.
135. Shaltoni HM, Yatsu FM, Hess DC. Statins and stroke prevention. Curr Atheroscler Rep 2005; 7: 313-8.
136. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
137. Burchfiel CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994; 25: 951-7.
138. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035-8.
139. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259: 1025-9.
140. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000; 32: 230-51
141. Ranganna K, Yatsu FM, Hayes BE. Butyrate, a small pleiotropic molecule with multiple cellular and molecular actions: its role as an anti-atherogenic agent. Recent Res Devel Mol Cell Biochem 2005; 2: 123-151.
142. Hu FB. Plant based foods and prevention of cardiovascular disease: an overview Am J Clin Nutr 2003; 78:544S-51S.
143. Koffman DM, Bazzare T, Mosca L, et al. An evaluation of Choose to Move 1999: an American Heart Association physical activity program for women. Arch Intern Med 2001; 161: 2193-9.
144. Melo LG, Gnecchi M, Pachori AS, Wang K, Dzau VJ. Gene- and cell-based therapies for cardiovascular diseases: current status and future directions. Eur Heart J 2004; 6: 24-35.
145. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 1999; 354: 1493-8.
146. McCarthy M. Molecular decoy may keep bypass grafts open. Lancet 2001; 358: 1703.
147. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
148. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-63.
149. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664- 71.
150. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999; 97: 431-4.
151. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
152. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995; 107: 181-6.
153. Perlman H, Suzuki E, Simonson M, Smith RC, Walsh K. GATA-6 induces p21 (Cip1) expression and G1 cell cycle arrest. J Biol Chem 1998; 273: 13713-8.
154. Smith RC, Branellec D, Gorski DH, et al. p21 CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev 1997; 11: 1674-89.
155. Narita N, Heikinheimo M, Bielinska M, White RA, Wilson DB. The gene for transcription factor GATA-6 resides on mouse chromosome 18 is expressed in myocardium and vascular smooth muscle. Genomics 1996; 36: 345-8.
156. Guo K, Andres V, Walsh K. Nitric oxide-induced downregulation of cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 1998; 97: 2066-72.
157. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21 (Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 1997; 272: 10050-7.
158. Guerin P, Sauzeau V, Rolli-Derkinderen M, et al. Stent implantation activates Rho A in human arteries: Inhibitory effect of rapamycin. J Vasc Res 2005; 42: 21-8.
159. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
160. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitoic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 1993; 90:9552-6.
161. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin- dependent kinases. Curr Med Chem 1999; 6: 859-75.
162. Kuntz RE, Baim DS. Prevention of coronary restenosis: the evolving evidence base for radiation therapy. Circulation 2000; 101: 2130-3.
163. King SB, Williams DO, Chougule P, et al. Endovascular β-radiation to reduce restenosis after coronary balloon angioplasty: results of the β-energy restenosis trial (BERT). Circulation 1998; 97: 2025-30.
164. Waksman R, Bhargava B, White L, et al. Intracoronary β-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000; 101: 1895-8.
165. Teirstein PS, King S. Vascular radiation in a drug-eluting world. It's not over till it's over. Circulation 2003; 108: 384-5.
166. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with β-emitting radiotherapy. Report of the proliferation reduction with vascular energy trial (PREVENT). Circulation 2000; 102: 951-8.
167. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell Cycle Progression: New Therapeutic Target for Vascular Proliferative Disease. Circulation 1998; 98: 82-9.
168. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating- cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8.
169. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 1994; 93: 2351-6.
170. Kutryk MJ, Foley DP, van den Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281 - 7.
171. Frimerman A, Welch PJ, Jin X, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999; 99: 697-03.
172. Tzeng E, Shears LL, Robbins PD, et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects of myointimal hyperplasia. Mol Med 1996; 2: 211-25.
173. Von der Leyen HE, Dzau DJ. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 2001; 103: 2760-5.
174. Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-41.
175. Yonemitsu Y, Kaneda Y, Hataa Y, Nakashima Y, Sueishi K. Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Ann NY Acad Sci 1997; 811: 395-9.
176. 2- production in the pig coronary artery. Circulation 1997; 96: 3593.
177. Freyschuss A, Stiko-Rahm A, Swedenborg J, et al. Antioxidant treatment inhibits the development if intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993; 91:1282-88.
178. Tulis DA, Durante W, Liu X, et al. Adenovirous-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation.Circulation 2001; 104: 2710-5.
179. Laukkanen MO, Kivela A, Rissane T, et al. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2002; 106: 1999-2003.
180. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982; 42:65-82.
181. Blottiere HM, Buecher B, Galmiche J-P, Cherbut C. Molecular analysis of the effect of short-chain fatty acids on intestinal cell proliferation. Proc Nutr Soc 2003; 62: 101-6.
182. Archer SY, Meng S, Shei A, Hodin RA. p21WAF1 is required for butyrate- mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci 1998;
183. Timmermann S, Lehrmann H, Polesskays A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001; 58: 728-36.
184. Davie JR. Nutritional genomics and proteomics in cancer prevention: Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485-93.
185. Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 Gene promoter through Sp1sites in a p53- negative human colon cancer cell line. J Biol Chem 1997: 272: 22199-06.
186. Ranganna K, Yousefipour Z, Yatsu FM, Milton SG, Hayes BE. Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation using cDNA array technology. Mol Cell Biochem 2003; 254: 21-36.
187. Ranganna K, Yatsu FM, Hayes BE, Milton SG, Jayakumar A. Butyrate inhibits proliferation-induced Proliferating Cell Nuclear Antigen expression (PCNA) in rat vascular smooth muscle cells. Mol Cell Biochem 2000; 205: 149 -61.
188. Ranganna K, Yatsu, FM. Inhibition of platelet-derived growth factor induced expression of glyceraldehyde 3-phosphate dehydrogenase by sodium butyrate in rat vascular smooth muscle cells. Atheroscler Thromb Vasc Biol 1997; 17: 3420-7.
189. Ranganna K, Joshi T, Yatsu FM. Sodium butyrate inhibits Platelet-derived growth factor-induced proliferation of vascular smooth muscle cells. Atheroscler Thromb Vasc Biol 1995: 15: 2273 -83.
190. Feng P, Ge L, Akyhani N, Liau G. Sodium butyrate is a potent modulator of smooth muscle cell proliferation and gene expression. Cell Prolif 1996; 29: 231-41.